Diabetes Metab J.  2011 Jun;35(3):236-242. 10.4093/dmj.2011.35.3.236.

The Effect of an Angiotensin Receptor Blocker on Arterial Stiffness in Type 2 Diabetes Mellitus Patients with Hypertension

• Kim JH
• Oh SJ
• Lee JM
• Hong EG
• Yu JM
• Han KA
• Min KW
• Son HS
• Chang SA

• KMID: 2175425
• DOI: http://doi.org/10.4093/dmj.2011.35.3.236

Abstract

BACKGROUND
Hypertension and type 2 diabetes mellitus are major risk factors for cardiovascular disease. This study analyzed the changes in central aortic waveforms and pulse wave velocity as well as related parameters after treatment with valsartan, an angiotensin II type 1 receptor blocker, in patients with type 2 diabetes and hypertension.
METHODS
We used pulse wave analysis to measure central aortic waveform in a total of 98 subjects. In 47 of these patients, pulse wave velocity measurements were obtained before and after 12 weeks of treatment with valsartan.
RESULTS
In the central aortic waveform analysis, the aortic pulse pressure and augmentation index were significantly decreased after valsartan treatment, as was the aortic pulse wave velocity. Factors contributing to the improvement in pulse wave velocity were the fasting blood glucose and haemoglobin A1c levels.
CONCLUSION
Short-term treatment with valsartan improves arterial stiffness in patients with type 2 diabetes and hypertension, and the glucose status at baseline was associated with this effect.

Keyword

Angiotensin receptor blocker; Arterial stiffness; Diabetes mellitus; Hypertension

MeSH Terms

Angiotensins
Arterial Pressure
Blood Glucose
Cardiovascular Diseases
Diabetes Mellitus
Diabetes Mellitus, Type 2
Fasting
Glucose
Humans
Hypertension
Pulse Wave Analysis
Receptor, Angiotensin, Type 1
Risk Factors
Tetrazoles
Valine
Vascular Stiffness
Valsartan
Angiotensins
Blood Glucose
Glucose
Receptor, Angiotensin, Type 1
Tetrazoles
Valine

Reference

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998. 339:229–234.

2. Cockcroft JR, Webb DJ, Wilkinson IB. Arterial stiffness, hypertension and diabetes mellitus. J Hum Hypertens. 2000. 14:377–380.

3. Lehmann ED, Gosling RG, Sonksen PH. Arterial wall compliance in diabetes. Diabet Med. 1992. 9:114–119.

4. Dart AM, Kingwell BA. Pulse pressure: a review of mechanisms and clinical relevance. J Am Coll Cardiol. 2001. 37:975–984.

5. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation. 2006. 113:664–670.

6. Agata J, Nagahara D, Kinoshita S, Takagawa Y, Moniwa N, Yoshida D, Ura N, Shimamoto K. Angiotensin II receptor blocker prevents increased arterial stiffness in patients with essential hypertension. Circ J. 2004. 68:1194–1198.

7. Karalliedde J, Smith A, DeAngelis L, Mirenda V, Kandra A, Botha J, Ferber P, Viberti G. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension. 2008. 51:1617–1623.

8. Okura T, Watanabe S, Kurata M, Koresawa M, Irita J, Enomoto D, Jotoku M, Miyoshi K, Fukuoka T, Higaki J. Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension. Clin Exp Hypertens. 2008. 30:415–422.

9. Pauca AL, O'Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension. 2001. 38:932–937.

10. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, Cockcroft JR, Webb DJ. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens. 1998. 16(12 Pt 2):2079–2084.

11. Nichols WW, O'Rourke MF. . McDonald's blood flow in arteries: theoretical, experimental and clinical principles. 1990. 3rd ed. London: Lea and Febier;77–142. 216–269. 283–359. 398–437.

12. Chemla D, Nitenberg A, Teboul JL, Richard C, Monnet X, le Clesiau H, Valensi P, Brahimi M. Subendocardial viability ratio estimated by arterial tonometry: a critical evaluation in elderly hypertensive patients with increased aortic stiffness. Clin Exp Pharmacol Physiol. 2008. 35:909–915.

13. Brooks BA, Molyneaux LM, Yue DK. Augmentation of central arterial pressure in type 2 diabetes. Diabet Med. 2001. 18:374–380.

14. Cohn JN, Finkelstein S, McVeigh G, Morgan D, LeMay L, Robinson J, Mock J. Noninvasive pulse wave analysis for the early detection of vascular disease. Hypertension. 1995. 26:503–508.

15. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation. 2002. 106:2085–2090.

16. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000. 52:11–34.

17. Williams B. Angiotensin II and the pathophysiology of cardiovascular remodeling. Am J Cardiol. 2001. 87(8A):10C–17C.

18. Johnston CI. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension. 1994. 23:258–268.

19. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, Imaizumi T. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension. 2004. 43:739–745.

20. Luft FC. Angiotensin, inflammation, hypertension, and cardiovascular disease. Curr Hypertens Rep. 2001. 3:61–67.

21. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000. 355:253–259.

22. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002. 359:995–1003.

23. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S. LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002. 359:1004–1010.

24. Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hofmayer D, Mohanty P, Tripathy D, Garg R. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab. 2003. 88:4496–4501.

25. Schling P, Loffler G. Effects of angiotensin II on adipose conversion and expression of genes of the renin-angiotensin system in human preadipocytes. Horm Metab Res. 2001. 33:189–195.

26. Tedesco MA, Natale F, Di Salvo G, Caputo S, Capasso M, Calabro R. Effects of coexisting hypertension and type II diabetes mellitus on arterial stiffness. J Hum Hypertens. 2004. 18:469–473.

27. Tropeano AI, Boutouyrie P, Pannier B, Joannides R, Balkestein E, Katsahian S, Laloux B, Thuillez C, Struijker-Boudier H, Laurent S. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006. 48:80–86.

28. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens. 2003. 21:3–12.

29. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy. Part I. Circulation. 2003. 108:1527–1532.

30. Wakabayashi I, Masuda H. Association of acute-phase reactants with arterial stiffness in patients with type 2 diabetes mellitus. Clin Chim Acta. 2006. 365:230–235.